Hypothesis

Chronic pharmacological attenuation of low‑grade pain signaling blunts hormetic gut‑brain‑immune pathways that mediate the longevity benefits of acarbose (and rapamycin), leading to reduced lifespan extension.

Mechanistic Rationale

• Mild, transient pain activates TRPV1‑dependent afferent signaling, which stimulates vagal afferents and triggers colonic release of short‑chain fatty acids (SCFAs) via microbiota‑immune crosstalk (see acarbose‑SCFA‑AMPK axis)【https://gethealthspan.com/science/article/acarbose-longevity-benefits-gut-microbiota】.
• SCFAs activate AMPK in enterocytes and hepatocytes, promoting autophagy, improving mitochondrial function, and extending lifespan【https://pmc.ncbi.nlm.nih.gov/articles/PMC5380489/】.
• NSAIDs and opioids suppress COX‑2/prostaglandin and μ‑opioid receptor signaling, thereby dampening the afferent pain signal and downstream vagal activation.
• Consequently, the hormetic increase in SCFA production and AMPK activation is attenuated, reducing the synergistic effect seen when acarbose is combined with rapamycin【https://gethealthspan.com/science/article/acarbose-and-rapamycin-longevity】.

Testable Predictions

1. Mice receiving chronic low‑dose ibuprofen will show a smaller increase in fecal SCFA concentrations after acarbose treatment compared with vehicle‑treated controls.
2. The same mice will exhibit reduced hepatic p‑AMPK phosphorylation and lower autophagic flux (LC3‑II/I ratio) in liver and intestine.
3. Lifespan extension conferred by acarbose (± rapamycin) will be significantly shortened in the ibuprofen‑treated cohort, returning to control levels.
4. Chemogenetic activation of TRPV1‑positive vagal afferents will rescue the SCFA/AMPK response and lifespan benefit despite NSAID presence.

Experimental Design

• Use male C57BL/6J mice, 4 months old, randomized to four groups: (1) control diet, (2) acarbose diet, (3) acarbose + ibuprofen (low dose in drinking water), (4) acarbose + ibuprofen + TRPV1 agonist (capsaicin low dose) or chemogenetic activation.
• Measure fecal SCFA (GC‑MS) at weeks 4, 8, 12; hepatic p‑AMPK and LC3 immunoblots at terminal; survival monitoring.
• Include sex‑specific cohort to assess dimorphism.

Potential Confounds

• Ibuprofen may independently affect gut microbiota; control with antibiotic‑treated microbiota transplant to isolate pain‑signaling effect.
• Opioid analgesia could be tested in parallel to confirm generality.

If the hypothesis holds, it would reframe analgesic use as a modulator of hormetic longevity pathways, suggesting that sparing, intermittent pain—or mimicking its neural signal—could be harnessed to enhance geroprotective interventions.